Next Article in Journal
Rising Trends in Hospitalizations for Cardiovascular Events among Young Cannabis Users (18–39 Years) without Other Substance Abuse
Next Article in Special Issue
Subclinical and Asymptomatic Atrial Fibrillation: Current Evidence and Unsolved Questions in Clinical Practice
Previous Article in Journal
Polypharmacy in Type 2 Diabetes Mellitus: Insights from an Internal Medicine Department
Previous Article in Special Issue
Detrimental Impact of Chronic Obstructive Pulmonary Disease in Atrial Fibrillation: New Insights from Umbria Atrial Fibrillation Registry
Open AccessReview

A Tale of Two Cities”: Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants

1
Department of Cardiology, AORN Ospedali dei Colli-Monaldi Hospital, 80131 Naples, Italy
2
Department of Translational Medical Sciences, University of Campania “Luigi Vanvitelli”, 80131 Naples, Italy
*
Author to whom correspondence should be addressed.
Medicina 2019, 55(8), 437; https://doi.org/10.3390/medicina55080437
Received: 30 June 2019 / Revised: 31 July 2019 / Accepted: 1 August 2019 / Published: 4 August 2019
(This article belongs to the Special Issue Stroke, Dementia and Atrial Fibrillation)
  |  
PDF [272 KB, uploaded 4 August 2019]
  |  

Abstract

Valvular heart disease and atrial fibrillation often coexist. Oral vitamin K antagonists have represented the main anticoagulation management for antithrombotic prevention in this setting for decades. Novel direct oral anticoagulants (DOACs) are a new class of drugs and currently, due to their well-established efficacy and security, they represent the main therapeutic option in non-valvular atrial fibrillation. Some new evidences are exploring the role of DOACs in patients with valvular atrial fibrillation (mechanical and biological prosthetic valves). In this review we explore the data available in the medical literature to establish the actual role of DOACs in patients with valvular heart disease and atrial fibrillation. View Full-Text
Keywords: novel oral anticoagulants; prosthetic valve replacement; atrial fibrillation novel oral anticoagulants; prosthetic valve replacement; atrial fibrillation
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited (CC BY 4.0).
SciFeed

Share & Cite This Article

MDPI and ACS Style

Palmiero, G.; Melillo, E.; Rubino, A.S. “A Tale of Two Cities”: Anticoagulation Management in Patients with Atrial Fibrillation and Prosthetic Valves in the Era of Direct Oral Anticoagulants. Medicina 2019, 55, 437.

Show more citation formats Show less citations formats

Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Metrics

Article Access Statistics

1

Comments

[Return to top]
Medicina EISSN 1010-660X Published by MDPI AG, Basel, Switzerland RSS E-Mail Table of Contents Alert
Back to Top